Where are we with postmenopausal hormone therapy in 2005?
Recently, two large randomized placebo-controlled studies on long-term postmenopausal hormone replacement therapy, the Heart and Estrogen/progestin Replacement Study (HERS) and the Women's Health Initiative (WHI), have raise a lot of controversies, especially on the cardiovascular aspects. We briefly review these two trials and discuss what we know and do not know about postmenopausal hormone therapy, including the evidence on novel choices such as raloxifene and tibolone.
Lam
Po M
PM
Department of Obstetrics and Gynecology, Prince of Wales Hospital, Hong Kong SAR, China. lamponmui@cuhk.edu.hk
Chung
Tony K H
TK
Haines
Christopher
C
D000368:Aged; D001943:Breast Neoplasms / Q000453:epidemiology; D003110:Colonic Neoplasms / Q000453:epidemiology; D003327:Coronary Disease / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D003704:Dementia / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000453:epidemiology; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000639:trends*; D005260:Female; D006620:Hip Fractures / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology; D010919:Placebos; D017698:Postmenopause; D011372:Progestins / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology; D020246:Venous Thrombosis / Q000453:epidemiology; D016387:Women's Health
D010919:Placebos; D011372:Progestins